JPS59175426A - Cariostatic agent - Google Patents

Cariostatic agent

Info

Publication number
JPS59175426A
JPS59175426A JP5120283A JP5120283A JPS59175426A JP S59175426 A JPS59175426 A JP S59175426A JP 5120283 A JP5120283 A JP 5120283A JP 5120283 A JP5120283 A JP 5120283A JP S59175426 A JPS59175426 A JP S59175426A
Authority
JP
Japan
Prior art keywords
acid
carboxylic acid
lactone
agent
nodulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP5120283A
Other languages
Japanese (ja)
Other versions
JPH0639375B2 (en
Inventor
Keiji Iguchi
井口 圭二
Masayoshi Fukuda
福田 正佳
Koichi Ogata
浩一 尾形
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KANEBO SHOKUHIN KK
Kracie Foods Ltd
Original Assignee
KANEBO SHOKUHIN KK
Kanebo Foods Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KANEBO SHOKUHIN KK, Kanebo Foods Ltd filed Critical KANEBO SHOKUHIN KK
Priority to JP5120283A priority Critical patent/JPH0639375B2/en
Publication of JPS59175426A publication Critical patent/JPS59175426A/en
Publication of JPH0639375B2 publication Critical patent/JPH0639375B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof

Abstract

PURPOSE:To provide a cariostatic agent free from the side effects such as the disturbance of the microflora in the body, the emergence of resistant microorganisms, etc., administrable continuously for a long period, and effective at a low concentration, by using a carboxylic acid used as a flavoring material or the carboxylic acid and a lactone as essential component. CONSTITUTION:The objective agent contains, as active component, a carboxylic acid used as a flavoring material, such as caprylic acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, rosin acid, vanillic acid, undecanoic acid, undecylenoic acid or enantoic acid, or a mixture of the above carboxylic acid and a lactone used as a flavoring material, e.g. d-decalactone, d-dodecalactone, d-undecalactone, d-tridecalactone, d-tetradecalactone, etc. as another cariostatic component. A high synergistic effect can be attained by the combined use of the above components.

Description

【発明の詳細な説明】 この発明は、抗結節剤、すなわち頗蝕を予防しまたはそ
の進行を阻止する口腔用剤に関するものである。
DETAILED DESCRIPTION OF THE INVENTION This invention relates to anti-nodular agents, ie, oral agents that prevent caries or arrest its progression.

近年、頗蝕すガわち虫歯の罹患率は著しく増大しており
、大きな社会問題にまで発展して跡る。
In recent years, the prevalence of dental caries has increased significantly, and it has developed into a major social problem.

一方、これに伴って1蝕の原因の研究も進んでおり、現
在の定説では1蝕の原因は食物中の蔗糖が勧蝕原因菌の
作用により変化を受は不溶性かつ粘着性のグルカンを生
成することにあるとされている。このようにして生成さ
れたグルカンによって結節原因菌が歯面に付着して増殖
し歯垢を形成する。そして、この歯垢をベースとしてそ
の中の細)  菌が糖発酵によシ酸を発生し、その酸に
より頗蝕が進行するのである。頗蝕の防止には歯の抵抗
性・  を高める方法、蔗糖を排除するか、蔗糖に代わ
る甘味料を使用する方法、蔗糖より生成する不溶性のグ
ルカンを分解するかまたはグルカンの生成を阻止する方
法もしくは頗蝕原因菌を撲滅する方法等が考えられる。
On the other hand, research into the cause of eclipse 1 is progressing, and the current theory is that sucrose in food undergoes changes due to the action of eclipse-causing bacteria, producing insoluble and sticky glucan. It is said that there is something to do. The glucan thus produced causes nodule-causing bacteria to adhere to the tooth surface and multiply, forming dental plaque. Using this plaque as a base, microorganisms within it ferment sugar and produce silicic acid, which causes caries to progress. To prevent caries, there are methods to increase tooth resistance, methods to eliminate sucrose or use a sweetener instead of sucrose, and methods to decompose insoluble glucan produced from sucrose or to block the production of glucan. Alternatively, methods for eradicating caries-causing bacteria may be considered.

上記の方法にはそれぞれ長所欠点を備えているが結節の
本質が飴蝕原因菌による感染症であるため、この原因と
なる結節原因菌を撲滅することが結節防止に最も効果的
であると考えられる。上記の菌としてはストレプトコッ
カスミュータンス(5treptococcus Mu
tans )やストレブトコツカスサングイス(5tr
eptococcus Sanguis )があげられ
る。結節防止のためにこのような結節原因菌を駆逐しよ
うとするこころみはこれまでも数多くなされている。例
えばペニシリンやエリスロマイシン等の抗生物質、結節
原因菌の細胞壁を溶解する細胞壁溶解酵素やシクロへキ
シジン等の殺菌剤の使用がととろみられている。しかし
ながら、これらは口腔内および腸内細菌叢の撹乱により
自然の細菌バランスを壊し、しかも副作用を惹起すると
いう問題がある。このような副作用の問題の解決がなさ
れていないだめ広く用いられるには致っていない。した
がって、もつかのところ結節防止のだめに決定的な方法
がないのが実情であり、食後、はぶらしで清掃するとい
う物理的な方法に勝る予防法の確立がなされていないの
が現状である。
Each of the above methods has advantages and disadvantages, but since the essence of nodule is an infection caused by the bacteria that causes caries, we believe that eradicating the nodule-causing bacteria is the most effective way to prevent nodule. It will be done. The above bacteria include Streptococcus Mutans.
tans) and Strebtococcus sanguis (5tr
eptococcus Sanguis). Many attempts have been made to eliminate such nodule-causing bacteria in order to prevent nodules. For example, the use of antibiotics such as penicillin and erythromycin, cell wall lytic enzymes that dissolve the cell walls of nodule-causing bacteria, and bactericidal agents such as cyclohexidine is gaining momentum. However, these have the problem of disrupting the natural bacterial balance by disturbing the oral and intestinal flora, and causing side effects. It has not been widely used until the problem of side effects has been resolved. Therefore, the reality is that there is no definitive way to prevent nodules, and no preventive method has been established that is superior to the physical method of cleaning with clothes after meals. .

本発明者らは、とのよりな事情に鑑み結節の防止を1指
して一連の研究を重ねているうち、ある種の香料に抗菌
作用があることにヒントを得て、香料を抗結節剤として
用いられ々いかと厖大な数の香料を対象とし、長期間に
渡って一連の研究を進めてきた。その結果、着香料(食
品香料)として用いられているカルボン酸をそのまま用
いるか、もしくはこのカルボン酸とカルボン酸と同じく
着香料として用いられているラクトンを組み合わせると
優れた1蝕原因菌殺菌効果が得られるようになることを
見いだしこの発明に到達した。すなわち、この発明は、
カルボン酸のみか、もしくはカルボン酸と下記の抗結節
成分とからなることを特徴とする抗結節剤をその要旨と
するものである。
In view of the above circumstances, the present inventors conducted a series of studies aimed at preventing nodules, and were inspired by the fact that certain fragrances have antibacterial effects. Over a long period of time, we have carried out a series of research on a huge number of fragrances that are used as fragrances. As a result, we found that using carboxylic acid, which is used as a flavoring agent (food flavoring) as it is, or combining this carboxylic acid with lactone, which is also used as a flavoring agent, has an excellent sterilizing effect on bacteria that cause caries. This invention was achieved by discovering that it can be obtained. That is, this invention:
The gist thereof is an anti-knot agent characterized by comprising only a carboxylic acid or a carboxylic acid and the following anti-knot component.

抗結節成分:ラクトン このように、この発明は、副作用が全くなく安全性の極
めて高い香料成分を結節剤として用いるところに最大の
特徴がある。
Anti-nodulation component: lactone As described above, the greatest feature of the present invention is that it uses an extremely safe fragrance component with no side effects as a nodulation agent.

つぎに、この発明の詳細な説明する。Next, this invention will be explained in detail.

従来、天然精油や天然精油の有効成分のうちの一部のも
のには大腸菌、赤痢菌等に対する抗菌作用があるという
報告が散見されている。しかしながら、カルボン酸のよ
うな着香料の抗菌性についての報告は殆ど見当らない。
Heretofore, there have been reports that natural essential oils and some of the active ingredients of natural essential oils have antibacterial effects against Escherichia coli, Shigella, and the like. However, there are almost no reports on the antibacterial properties of flavoring agents such as carboxylic acids.

そこで本発明者らは、まづ、第1段階として比較的汎用
されているカルボン酸を対象としミュータンス菌に対す
る抗菌活性を測定した。抗菌活性は、それぞれカルボン
酸を5チのアルコール溶液としくこれを供試成分とする
)、これを、5チの蔗糖を含有するハートインフュージ
ョン培地に1/100〜1/1000の割合(5係アル
コール溶液((供試成分))濃度が1/lo。
Therefore, as a first step, the present inventors measured the antibacterial activity against Streptococcus mutans using carboxylic acids, which are relatively widely used. The antibacterial activity was determined by adding a 1/100 to 1/1000 ratio of carboxylic acid to a heart infusion medium containing 5 parts sucrose (5 parts alcohol solution as the test component). The alcohol solution ((test component)) concentration is 1/lo.

〜1/1000 )になるように添加し、培地が固化し
たのち、ミュータンス菌(ストレプトコッカスミュータ
ンスRIMD 8125001 )を穿刺接種して37
°Cで72時間以上培養し、培地中、培地表面における
菌の生育を観察して測定した。抗ミュータンス菌活性が
あるものは後記の第1表のとおりである。抗ミュータン
ス菌活性があるということは、供試成分を171000
の割合になるように添加し、37°Cで72時間以上培
養した場合においてミュータンス菌の生育が認められな
いということである。そして、供試成分濃度をどんどん
希釈してゆき、抗ミュータンス菌活性が認められる最少
濃度(有効生育阻止濃度)の逆数2例えば供試成分濃度
が1/1000であるときは、その逆数の1000を抗
ミュータンス菌活性値として示しだ。対象用として厚朴
エキス、厚朴エキスの有効成分であるマグノロールなら
びにミュータンス菌に対する殺菌作用をもつ抗生物質エ
リスロマイシンを用い、同様の実験を行って第1表に併
せて示した。第1表に掲げるカルボン酸は、抗頗蝕用剤
として知られている厚朴エキス(特開昭57−8531
9参照)と同等かそれ以上の優れた抗ミュータンス菌活
性を示している。
After the medium had solidified, mutans bacteria (Streptococcus mutans RIMD 8125001) was punctured and inoculated to 37
The cells were cultured at °C for 72 hours or more, and the growth of bacteria in the medium and on the surface of the medium was observed and measured. Those having anti-Streptococcus mutans activity are shown in Table 1 below. Anti-Streptococcus mutans activity means that the test ingredient has 171,000
Streptococcus mutans was added at a ratio of 50% and cultured at 37°C for 72 hours or more, and no growth of Streptococcus mutans was observed. Then, the concentration of the test component is gradually diluted.For example, if the concentration of the test component is 1/1000, is shown as the anti-Streptococcus mutans activity value. Similar experiments were conducted using Atsuboku extract, Magnolol, which is an active ingredient of Atsubaku extract, and erythromycin, an antibiotic that has a bactericidal effect against Streptococcus mutans, and are shown in Table 1. The carboxylic acids listed in Table 1 are known as Koboku extract (Japanese Patent Application Laid-Open No. 57-8531), which is known as an anti-caries agent.
9) shows an excellent anti-Streptococcus mutans activity that is equivalent to or better than that of Streptococcus mutans.

このように、カルボン酸が極めて抗ミュータンス菌活性
に富んでいることより探索範囲をカルボン酸と同じく着
香料として用いられているラクトンの分野まで広げて抗
ミュータンス菌活性のある物質を調べた。その結果は後
記の第2表のとおりであり、同表に掲げるラクトンが極
めて高い抗ミニータンス菌活性を備えていた。
Since carboxylic acids are extremely rich in anti-Streptococcus mutans activity, we expanded our search to include lactones, which are used as flavoring agents like carboxylic acids, to investigate substances with anti-Streptococcus mutans activities. . The results are shown in Table 2 below, and the lactones listed in the table had extremely high anti-minitans activity.

つぎに、上記第1表および第2表に示す香料成分を混合
してその抗ミュータンス菌活性を調べた。
Next, the fragrance components shown in Tables 1 and 2 above were mixed and their anti-Streptococcus mutans activity was examined.

その結果は後記の第3表に示すとおりであり、それぞれ
第1表および第2表の香料成分の抗ミュータンス菌活性
値の相加平均よりも高い抗ミュータンス菌活性値が得ら
れた。これは第1表および第2表に示す香料成分を混合
するととにより大きな相乗効果が得られることを示して
いる。すなわち、一般に、カルボン酸のような着香料は
単独で使用されることは稀であり、各種の成分を調合し
て所望の香りのものをつくり、これを使用することが行
われている。したがって、第1表および第2表に示す香
料成分を混合して用いることにより第8表に示すような
大きな相乗効果が得られるようになるということは実用
上極めて有効である。
The results are shown in Table 3 below, and the anti-Streptococcus mutans activity values were higher than the arithmetic mean of the anti-Streptococcus mutans activity values of the fragrance ingredients in Tables 1 and 2, respectively. This shows that a greater synergistic effect can be obtained by mixing the fragrance ingredients shown in Tables 1 and 2. That is, in general, flavoring agents such as carboxylic acids are rarely used alone, and various components are mixed to create a desired fragrance and then used. Therefore, it is extremely effective in practice that the large synergistic effects shown in Table 8 can be obtained by mixing and using the fragrance ingredients shown in Tables 1 and 2.

このように、この発明の抗結節剤は、食品業界等で幅広
く、実除に使用されている安全性の高い香料成分からな
るため副作用は全く生じない。すなわち、この発明の抗
結節剤は抗生物質であるエリスロマイシンに比べればそ
の抗結節作用がやや低いが、この発明の抗結節剤は抗生
物質ではないため抗生物質にみられるような副作用(体
内微生物相の撹乱、耐性菌の出現)がなく、長期間連用
しても全く問題はない。そのうえ、この発明の抗結節剤
はカルボン酸、ラクトン等幅広い範囲の香料成分からな
るだめ、適宜の香料成分を組み合わせて、抗帖蝕剤の添
加の対象となる品物に任意の好ましい風味を付与しつる
ようになる。この効果は、抗結節剤の投与がある程度長
期間に渡ること、また、ことに結節予防のためには歯牙
の助出がはじまる1才前後からの幼児における投与が望
ましいことも考え合わせると臨床実用上、極めて有用性
の高いものである。
As described above, the anti-nodulation agent of the present invention does not cause any side effects because it is composed of a highly safe flavoring ingredient that is widely used in the food industry and other areas to remove knots. In other words, the anti-nodulation agent of this invention has a slightly lower anti-nodulation effect than the antibiotic erythromycin, but since the anti-nodulation agent of this invention is not an antibiotic, it does not cause side effects (in vivo microflora) that are seen with antibiotics. (disturbance of bacteria, emergence of resistant bacteria), and there is no problem at all even if used continuously for a long period of time. Furthermore, the anti-nodulation agent of the present invention is composed of a wide range of flavoring ingredients such as carboxylic acids and lactones, and can be combined with appropriate flavoring ingredients to impart any desired flavor to the product to which the anti-nodulation agent is added. It becomes like a vine. This effect is clinically practical, considering that anti-nodulation agents can be administered for a fairly long period of time, and that to prevent nodules, it is desirable to administer them to infants from around 1 year of age, when tooth development begins. Moreover, it is extremely useful.

さらに、この発明の抗結節剤は極めて低濃度でミュータ
ンス菌の生育を阻止することができるため、微量の使用
量で大きな抗陥蝕効果を得ることができる。
Further, since the anti-nodulation agent of the present invention can inhibit the growth of S. mutans at an extremely low concentration, a large anti-cavity effect can be obtained with a small amount of use.

このように、この発明の抗頗蝕剤は、香料成分であって
しかt微量の使用量で優れた抗結節効果が得られるため
、うがい薬、トローチ、はみかき。
As described above, the anti-caries agent of the present invention is a fragrance ingredient and can have an excellent anti-nodule effect even when used in a very small amount, so it can be used in gargles, troches, and toothpastes.

チューインガム等を賦香すると同時に抗結節効果も発揮
しうるのである。そして、その使用により従来の抗生物
質のような副作用が全く生じないのであり、長期間の連
用に充分に耐えうる極めて実用性の高いものである。
It can flavor chewing gum and the like and at the same time exhibit an anti-knot effect. Moreover, its use does not cause any side effects unlike those of conventional antibiotics, and it is highly practical as it can withstand long-term continuous use.

(以 下 余 白) 第   3   表 つぎに、実施例について説明する。(Hereafter, extra white) Table 3 Next, examples will be described.

以下の実施例では混合によシ優れた相乗効果が得られる
第3表の混合物を用いて行った。
The following examples were carried out using the mixtures shown in Table 3, which give excellent synergistic effects upon mixing.

〔実施例1〕 第3表に記載された磁1の混合物を対象とし、これのミ
ュータンス菌活性を求めたところ、ミュータンス菌に対
する有効生育阻止濃度はl/4000(抗ミュータンス
菌活性4000 )であった。この&1混合物の5%ア
ルコール溶液を濃度10%の蔗糖溶液に1/4000の
割合で添加して口に含んでも違和感および刺激は全く感
じられなかった。
[Example 1] When the Streptococcus mutans activity was determined using the mixture of Magnetic 1 listed in Table 3, the effective growth-inhibiting concentration against Streptococcus mutans was 1/4000 (anti-Streptococcus mutans activity 4000). )Met. Even when a 5% alcohol solution of this &1 mixture was added to a 10% sucrose solution at a ratio of 1/4000 and put into the mouth, no discomfort or irritation was felt at all.

〔実施例2〕 第3表の隘2の混合物を対象とし、これのミュタンス菌
に対する有効生育阻止濃度を調べたところその有効生育
阻止濃度は1/4000 (抗ミュータンス菌活性40
00 )であった。この混合物の5%アルコール溶液を
濃度10%の蔗糖溶液にl/4000の割合で添加して
口に含んでも違和感および刺激は全く感じられなかった
[Example 2] The effective growth inhibitory concentration against Streptococcus mutans was investigated using the mixture in column 2 of Table 3.
00). Even when a 5% alcohol solution of this mixture was added to a 10% sucrose solution at a ratio of l/4000 and put into the mouth, no discomfort or irritation was felt at all.

特許出願人カネボウ食品株式会社 代理人 弁理士 西 藤 征 彦 手続補正書 (自発) 1、事件の表示 昭和58年特許願第51202号 2、 発明の名称 抗結節剤 3、補正をする者 事件との関係  特許出願人 な    し 7、補正の内容 (1)明細書第10頁第1表の物質名の欄の第5行目に
おいて、「ステアリン酸」とあるを「ステアリン酸」と
訂正する。
Patent applicant Kanebo Foods Co., Ltd. Representative Patent attorney Yukihiko Nishifuji Procedural amendment (spontaneous) 1. Indication of the case Patent Application No. 51202 of 1982 2. Name of the invention Anti-nodulation agent 3. Case of the person making the amendment No patent applicant 7. Contents of the amendment (1) In the fifth line of the substance name column of Table 1 on page 10 of the specification, "stearic acid" is corrected to "stearic acid."

(2)添付の委任状を補充する。(2) Supplement the attached power of attorney.

8、添付書類の目録8. List of attached documents

Claims (2)

【特許請求の範囲】[Claims] (1)カルボン酸のみかもしくはカルボン酸と下記の抗
結節成分とからなることを特徴とする抗結節剤。 抗帖蝕成分:ラクトン
(1) An anti-knot agent characterized by comprising only a carboxylic acid or a carboxylic acid and the following anti-knot ingredient. Anti-corrosion ingredient: lactone
(2)カルボン酸が、カプリン酸、ラウリン酸。 ミリスチン酸、バルミチン酸、ステアリン酸、オレイン
酸、リノール酸、ロジン酸、バニリン酸。 ウンデカン酸、ウンデカン酸およびエナ/ト酸からなる
群から選ばれた少なくとも一つのカルボン酸である特許
請求の範囲第1項記載の抗結節剤5(3)抗結節成分の
ラクトンが、d−デカラクトン、d−ドデカラクトン、
d−ウンデカラクトンd−)リデカラクトンおよびd−
テトラデカラクトンからなる群から選ばれた少なくとも
一つのラクトンである特許請求の範囲第1項記載の抗結
節剤。
(2) The carboxylic acid is capric acid or lauric acid. Myristic acid, valmitic acid, stearic acid, oleic acid, linoleic acid, rosin acid, vanillic acid. The lactone of the anti-nodulation agent 5(3) anti-nodulation component according to claim 1, which is at least one carboxylic acid selected from the group consisting of undecanoic acid, undecanoic acid and ena/tonic acid, is d-decalactone. , d-dodecalactone,
d-Undecalactone d-) Ridecalactone and d-
The anti-nodulation agent according to claim 1, which is at least one lactone selected from the group consisting of tetradecalactone.
JP5120283A 1983-03-26 1983-03-26 Anti-caries agent Expired - Lifetime JPH0639375B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP5120283A JPH0639375B2 (en) 1983-03-26 1983-03-26 Anti-caries agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5120283A JPH0639375B2 (en) 1983-03-26 1983-03-26 Anti-caries agent

Publications (2)

Publication Number Publication Date
JPS59175426A true JPS59175426A (en) 1984-10-04
JPH0639375B2 JPH0639375B2 (en) 1994-05-25

Family

ID=12880303

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5120283A Expired - Lifetime JPH0639375B2 (en) 1983-03-26 1983-03-26 Anti-caries agent

Country Status (1)

Country Link
JP (1) JPH0639375B2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180483A2 (en) * 1984-11-02 1986-05-07 Advanced Oral Healthcorp Limited Oral fine dispersions sprays and emulsions
JPS61260017A (en) * 1985-05-15 1986-11-18 Rooto Seiyaku Kk Composition for oral cavity application having caries-preventive effect
JPS63190816A (en) * 1986-09-05 1988-08-08 Taiyo Koryo Kk Growth inhibitor for cariogenic bacteria
JPH01246214A (en) * 1988-03-28 1989-10-02 Shiseido Co Ltd Composition for oral cavity
JPH03167114A (en) * 1989-11-24 1991-07-19 Mikimoto Seiyaku Kk Composition for oral cavity
WO1998043601A1 (en) * 1997-03-28 1998-10-08 Min Byung Moo Pharmaceutical composition, containing medium-chain fatty acids as active ingredients, for dental caries and periodontal disease
JP2009142987A (en) * 2009-03-30 2009-07-02 Kobe Steel Ltd Fatigue strength improvement working method of crankshaft and its working device

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180483A2 (en) * 1984-11-02 1986-05-07 Advanced Oral Healthcorp Limited Oral fine dispersions sprays and emulsions
JPS61260017A (en) * 1985-05-15 1986-11-18 Rooto Seiyaku Kk Composition for oral cavity application having caries-preventive effect
JPS63190816A (en) * 1986-09-05 1988-08-08 Taiyo Koryo Kk Growth inhibitor for cariogenic bacteria
JPH0236567B2 (en) * 1986-09-05 1990-08-17 Taiyo Koryo Kk
JPH01246214A (en) * 1988-03-28 1989-10-02 Shiseido Co Ltd Composition for oral cavity
JPH03167114A (en) * 1989-11-24 1991-07-19 Mikimoto Seiyaku Kk Composition for oral cavity
WO1998043601A1 (en) * 1997-03-28 1998-10-08 Min Byung Moo Pharmaceutical composition, containing medium-chain fatty acids as active ingredients, for dental caries and periodontal disease
JP2009142987A (en) * 2009-03-30 2009-07-02 Kobe Steel Ltd Fatigue strength improvement working method of crankshaft and its working device

Also Published As

Publication number Publication date
JPH0639375B2 (en) 1994-05-25

Similar Documents

Publication Publication Date Title
EP1776944B1 (en) Oral care and food compositions comprising isocamphylcyclohexanol
JP4731323B2 (en) Periodontal disease treatment and / or prevention composition
JPS59175410A (en) Cariostatic agent
JP3614479B2 (en) Periodontal disease-causing bacteria or caries-causing bacteria inhibitor, oral composition and food containing them
JPS61171423A (en) Drug for alleviating dental caries and periodontosis
CN108042420A (en) A kind of composition and its application for oral health
JPS59175426A (en) Cariostatic agent
JPS59175422A (en) Cariostatic agent
JP7445910B2 (en) Oral compositions, oral care products, and foods containing oral resident bacteria regulators
JPH04164021A (en) Composition for oral cavity
JP6249438B2 (en) Oral hygiene improving active composition
JP4011787B2 (en) Selective antimicrobial composition
JPS59175423A (en) Cariostatic agent
JP2004250374A (en) Composition for oral cavity
WO2021079921A1 (en) Growth inhibitor for pathogenic bacteria in oral cavity, oral microflora improver, and composition for oral cavity
JPS5835484B2 (en) Oral composition
JP2004010497A (en) Oral composition
JPH0320364B2 (en)
JP6921655B2 (en) Protease inhibitors, biofilm formation inhibitors, and oral compositions
JPS641441B2 (en)
RU1790941C (en) Remedy for bath
KR20230111669A (en) Sustained-release patch containing natural extracts as active ingredients
JPS604126A (en) Inhibitor against growth of dental bacteria
JP2005082568A (en) Glucosyltransferase inhibitor, plaque formation inhibitor, antibacterial agent, agent for oral cavity, and beverage or food for preventing caries
JP2021065176A (en) Agent for inhibiting oral cavity pathogenic bacterium from growing, composition for oral cavity, and accelerator